Skip to main content
Signal8

WINDWARD BIO GROUP AG Form 424B4 — Nov 13, 2026

Form 424B4Filed Nov 13, 2026, 6:33 PM ET0001193125-26-461203Original filing

Windward Bio Group AG, a Swiss clinical-stage biotech developing ultra-long-acting antibodies for asthma, COPD and atopic dermatitis, priced its IPO at $17.00 per share, offering 10,294,117 common shares for gross proceeds of approximately $175.0 million. The shares will list on Nasdaq under the symbol WWB, with Jefferies, TD Cowen, Piper Sandler and UBS Investment Bank as underwriters. Concurrent with the IPO, Sanofi has agreed to purchase 1,532,691 common shares plus pre-funded warrants for an aggregate $50.0 million at the same $17.00 price, expected to close alongside the offering.

Key figures

Gross Proceeds
174999989
Offering Price
17
Shares Offered
10294117
Greenshoe
1544117
Net loss fy2025
$48.3 million
Net loss h1 2026
$42.6 million
Cash june 30 2026
$207.3 million
Reverse share split
3-for-2, effective November 6, 2026
Net proceeds estimate
$203.8 million (or $228.0 million if greenshoe fully exercised)
Pro forma cash as adjusted
$411.1 million
Concurrent private placement
$50.0 million Sanofi purchase of 1,532,691 shares plus pre-funded warrants on 1,408,485 shares
Preliminary cash sept 30 2026
$181.8 million
Accumulated losses june 30 2026
$93.2 million
Underwriting discount per share
1.19
Total shares outstanding post offering
58,038,748 (or 59,582,865 with full greenshoe)

AI analysis

Red flags7 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.